StreetInsider.com News Articles

Form 6-K Almonty Industries Inc. For: Jul 17

Mon, 20 Jul 2026 06:01:00 -0400

si-local-file:///var/storage/secattach/20260720/26786413.html

Form 6-K Almonty Industries Inc. For: Jul 17

Mon, 20 Jul 2026 06:01:00 -0400

si-local-file:///var/storage/secattach/20260720/26786413.html

Almirall Announces EMA Acceptance for Filing of Paediatric Registration of Ebglyss (Lebrikizumab) in Atopic Dermatitis in Children 6 Months and Older

Mon, 20 Jul 2026 04:00:00 -0400

The EMA application is supported by data from the paediatric clinical programme for lebrikizumab, including the pivotal Phase III ADorable-1 study and the ADorable-2 long-term extension study.
Atopic dermatitis affects a significant number of children and adolescents and often peaks in childhood – with around 60% of cases appearing within the first year of life1.
As atopic dermatitis often begins early in life and can have a lasting impact on patients and their families, effective disease control is increasingly recognised as an important opportunity to reduce long-term disease burden and support healthier life trajectories2.

BARCELONA, Spain--(BUSINESS WIRE)-- Almirall, S.A.

Almirall Announces EMA Acceptance for Filing of Paediatric Registration of Ebglyss (Lebrikizumab) in Atopic Dermatitis in Children 6 Months and Older

Mon, 20 Jul 2026 04:00:00 -0400

The EMA application is supported by data from the paediatric clinical programme for lebrikizumab, including the pivotal Phase III ADorable-1 study and the ADorable-2 long-term extension study.
Atopic dermatitis affects a significant number of children and adolescents and often peaks in childhood – with around 60% of cases appearing within the first year of life1.
As atopic dermatitis often begins early in life and can have a lasting impact on patients and their families, effective disease control is increasingly recognised as an important opportunity to reduce long-term disease burden and support healthier life trajectories2.

BARCELONA, Spain--(BUSINESS WIRE)-- Almirall, S.A.

Almirall Announces EMA Acceptance for Filing of Paediatric Registration of Ebglyss (Lebrikizumab) in Atopic Dermatitis in Children 6 Months and Older

Mon, 20 Jul 2026 04:00:00 -0400

The EMA application is supported by data from the paediatric clinical programme for lebrikizumab, including the pivotal Phase III ADorable-1 study and the ADorable-2 long-term extension study.
Atopic dermatitis affects a significant number of children and adolescents and often peaks in childhood – with around 60% of cases appearing within the first year of life1.
As atopic dermatitis often begins early in life and can have a lasting impact on patients and their families, effective disease control is increasingly recognised as an important opportunity to reduce long-term disease burden and support healthier life trajectories2.

BARCELONA, Spain--(BUSINESS WIRE)-- Almirall, S.A.

Almirall Announces EMA Acceptance for Filing of Paediatric Registration of Ebglyss (Lebrikizumab) in Atopic Dermatitis in Children 6 Months and Older

Mon, 20 Jul 2026 04:00:00 -0400

The EMA application is supported by data from the paediatric clinical programme for lebrikizumab, including the pivotal Phase III ADorable-1 study and the ADorable-2 long-term extension study.
Atopic dermatitis affects a significant number of children and adolescents and often peaks in childhood – with around 60% of cases appearing within the first year of life1.
As atopic dermatitis often begins early in life and can have a lasting impact on patients and their families, effective disease control is increasingly recognised as an important opportunity to reduce long-term disease burden and support healthier life trajectories2.

BARCELONA, Spain--(BUSINESS WIRE)-- Almirall, S.A.

Almirall Announces EMA Acceptance for Filing of Paediatric Registration of Ebglyss (Lebrikizumab) in Atopic Dermatitis in Children 6 Months and Older

Mon, 20 Jul 2026 04:00:00 -0400

The EMA application is supported by data from the paediatric clinical programme for lebrikizumab, including the pivotal Phase III ADorable-1 study and the ADorable-2 long-term extension study.
Atopic dermatitis affects a significant number of children and adolescents and often peaks in childhood – with around 60% of cases appearing within the first year of life1.
As atopic dermatitis often begins early in life and can have a lasting impact on patients and their families, effective disease control is increasingly recognised as an important opportunity to reduce long-term disease burden and support healthier life trajectories2.

BARCELONA, Spain--(BUSINESS WIRE)-- Almirall, S.A.

Almirall Announces EMA Acceptance for Filing of Paediatric Registration of Ebglyss (Lebrikizumab) in Atopic Dermatitis in Children 6 Months and Older

Mon, 20 Jul 2026 04:00:00 -0400

The EMA application is supported by data from the paediatric clinical programme for lebrikizumab, including the pivotal Phase III ADorable-1 study and the ADorable-2 long-term extension study.
Atopic dermatitis affects a significant number of children and adolescents and often peaks in childhood – with around 60% of cases appearing within the first year of life1.
As atopic dermatitis often begins early in life and can have a lasting impact on patients and their families, effective disease control is increasingly recognised as an important opportunity to reduce long-term disease burden and support healthier life trajectories2.

BARCELONA, Spain--(BUSINESS WIRE)-- Almirall, S.A.

Almirall Announces EMA Acceptance for Filing of Paediatric Registration of Ebglyss (Lebrikizumab) in Atopic Dermatitis in Children 6 Months and Older

Mon, 20 Jul 2026 04:00:00 -0400

The EMA application is supported by data from the paediatric clinical programme for lebrikizumab, including the pivotal Phase III ADorable-1 study and the ADorable-2 long-term extension study.
Atopic dermatitis affects a significant number of children and adolescents and often peaks in childhood – with around 60% of cases appearing within the first year of life1.
As atopic dermatitis often begins early in life and can have a lasting impact on patients and their families, effective disease control is increasingly recognised as an important opportunity to reduce long-term disease burden and support healthier life trajectories2.

BARCELONA, Spain--(BUSINESS WIRE)-- Almirall, S.A.

Almirall Announces EMA Acceptance for Filing of Paediatric Registration of Ebglyss (Lebrikizumab) in Atopic Dermatitis in Children 6 Months and Older

Mon, 20 Jul 2026 04:00:00 -0400

The EMA application is supported by data from the paediatric clinical programme for lebrikizumab, including the pivotal Phase III ADorable-1 study and the ADorable-2 long-term extension study.
Atopic dermatitis affects a significant number of children and adolescents and often peaks in childhood – with around 60% of cases appearing within the first year of life1.
As atopic dermatitis often begins early in life and can have a lasting impact on patients and their families, effective disease control is increasingly recognised as an important opportunity to reduce long-term disease burden and support healthier life trajectories2.

BARCELONA, Spain--(BUSINESS WIRE)-- Almirall, S.A.

Almirall Announces EMA Acceptance for Filing of Paediatric Registration of Ebglyss (Lebrikizumab) in Atopic Dermatitis in Children 6 Months and Older

Mon, 20 Jul 2026 04:00:00 -0400

The EMA application is supported by data from the paediatric clinical programme for lebrikizumab, including the pivotal Phase III ADorable-1 study and the ADorable-2 long-term extension study.
Atopic dermatitis affects a significant number of children and adolescents and often peaks in childhood – with around 60% of cases appearing within the first year of life1.
As atopic dermatitis often begins early in life and can have a lasting impact on patients and their families, effective disease control is increasingly recognised as an important opportunity to reduce long-term disease burden and support healthier life trajectories2.

BARCELONA, Spain--(BUSINESS WIRE)-- Almirall, S.A.

Almirall Announces EMA Acceptance for Filing of Paediatric Registration of Ebglyss (Lebrikizumab) in Atopic Dermatitis in Children 6 Months and Older

Mon, 20 Jul 2026 04:00:00 -0400

The EMA application is supported by data from the paediatric clinical programme for lebrikizumab, including the pivotal Phase III ADorable-1 study and the ADorable-2 long-term extension study.
Atopic dermatitis affects a significant number of children and adolescents and often peaks in childhood – with around 60% of cases appearing within the first year of life1.
As atopic dermatitis often begins early in life and can have a lasting impact on patients and their families, effective disease control is increasingly recognised as an important opportunity to reduce long-term disease burden and support healthier life trajectories2.

BARCELONA, Spain--(BUSINESS WIRE)-- Almirall, S.A.

Almonty to Voluntarily Delist From TSX

Fri, 17 Jul 2026 17:30:00 -0400

DILLON, Mont.--(BUSINESS WIRE)-- Almonty Industries Inc. (“Almonty” or the “Company”) (NASDAQ: ALM) (TSX: AII) (ASX: AII) (Frankfurt: ALI1), a leading global producer of tungsten concentrate, today announced that it will voluntarily delist the common shares of the Company (the “Common Shares”) from the Toronto Stock Exchange (the “TSX”) effective as of the close of trading on July 31, 2026 (the “Delisting”). Following such date, the Common Shares will no longer be traded on the TSX, but will continue to trade on the Nasdaq Capital Market (the “Nasdaq”) under the symbol ALM.